Josh Hardy, first-grader taking Chimerix’s brincidofovir, leaves ICU

Posted by John Murawski on March 27, 2014 

Seven-year-old Josh Hardy, shown in May 2013 photo, was treated for malignant rhabdoid tumor at St. Jude's when he was nine months old. He's been cancer free for more than two years and has been raising money for St. Jude's with his kindergarten class at Hugh Mercer Elementary.

PETER CIHELKA — The Free Lance-Star

A critically ill first-grader taking an experimental medication made by Durham drug developer Chimerix has been moved out of intensive care and is improving dramatically, his mother said.

Josh Hardy, 7, became the first patient to take Chimerix’s antiviral, brincidofovir, as part of a small trial hastily arranged two weeks ago by Chimerix after the boy’s family mounted a social media campaign to obtain the medication.

Since Josh’s first infusion, the potentially lethal adenovirus has almost disappeared, his mother posted on Facebook on Tuesday. “Pretty much gone!,” Aimee Hardy wrote. “We are still waiting for his kidney function to return but we are definitely on the right path. Josh has made tremendous strides in the last week.”

Josh, a four-time cancer survivor, has been hospitalized at St. Jude Children’s Research Hospital in Tennessee since late December.

Chimerix and St. Jude have said they would not provide updates on Josh’s condition, making Aimee Hardy’s Facebook page an unofficial and unconfirmed source of information on bricidofovir’s effectiveness at wiping out a potent virus without toxic side effects.

Chimerix initially rebuffed the family’s pleas for help, resulting in death threats and an armed escort for the 54-employee company’s CEO, Kenneth Moch.

Chimerix stock closed at $24.06 on Thursday, down 10 cents a share.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service